ABSTRACT
Obesity is a substantial public health challenge across the globe. The use of resistant starch has been proposed as a probable management strategy for complications of obesity. We investigated the effects of resistant starch intake on lipid profiles, glucose metabolism, antioxidant status, lipid peroxidation marker, blood pressure, and anthropometric variables in subjects with overweight or obesity. In this 12-week, randomized, double-blind, placebo-controlled, 2 × 2 crossover trial, 21 Participants (mean age, 35 ± 7.0 years; body mass index, 32.4 ± 3.5 kg/m²) were given 13.5 g Hi-Maize 260 or placebo daily for 4 weeks, separated by a 4-week washout period. Changes in total antioxidant status (p = 0.04) and serum concentrations of insulin in 52.4% participants with insulin levels above 16 µIU/mL at the baseline (p = 0.04) were significantly different in the three phases. In addition, the mean of serum high-density lipoprotein cholesterol after the intervention was significantly higher than after baseline value (p = 0.04). We found no significant differences in serum concentrations of total cholesterol, triacylglycerol, low-density lipoprotein cholesterol, fasting blood sugar, insulin, homeostatic model assessment of insulin resistance, quantitative insulin sensitivity check index, superoxide dismutase activity, malondialdehyde, blood pressure, and anthropometric variables in the three phases of baseline, after intervention with resistant starch and after placebo. Resistant starch consumption improved serum insulin concentrations, lipid profiles, and antioxidant status in subjects with overweight or obesity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01992783
Subject(s)
Adult , Humans , Blood Glucose , Blood Pressure , Body Mass Index , Cholesterol , Dietary Fiber , Fasting , Glucose , Insulin , Insulin Resistance , Lipid Metabolism , Lipid Peroxidation , Lipoproteins , Malondialdehyde , Metabolism , Obesity , Overweight , Oxidative Stress , Public Health , Starch , Superoxide Dismutase , TriglyceridesABSTRACT
Background: testicular function is modified by maturational gonadostatic control highly susceptible to negative physiologic niche-altering factors like UV-rays
Objective: this study was performed in order to uncover new aspects of Compact Florescent Lamps [CFLs] induced damages on the testicular tissue of rats and evaluating the effect of curcumin on testis of rats after exposure to compact florescent Lamps
Materials and Methods: twenty-four adult male Albino rats were randomly divided into three groups: control group [ethyl oleate 0.2 ml, IP, for 45 days, without CFLs exposure], fluorescent group [ethyl oleate 0.2 ml, IP, daily and treated with 12 hr. CFLs exposure for 45 days] and curcumin group [curcumin 20 micro M, IP along with 12 hr. CFLs exposure for 45 days]. The rats were anesthetized at the end of the experiment. Gonadotropin hormones and prolactin levels were measured; Histopathological and histomorphometrical analysis of the testis was carried out
Results: results of this study showed that CFLs significantly decreased serum levels of follicle stimulating hormone, prolactin, testicular weight, sperm motility, TDI, and SPI. Furthermore, CFLs had no effect on serum levels of luteinizing hormone and sperm count and also, increased abnormal sperm shapes. Our results also showed that curcumin supplementation following CFLs reversed these alterations
Conclusion: these results strongly suggest that CFLs severely impairs testis while curcumin as an antioxidant had protective effects on undesirable effects in testis induced by CFLs
ABSTRACT
Correlation between Helicobacter pylori infection and blood group typing has been widely evaluated in both patients and healthy population. However, data addressing this correlation in hemodialysis patients are scarce. The aim of this study was to evaluate the prevalence of anti-Helicobacter pylori and anticytotoxin-associated gene A [anti-Cag A] antibodies and their correlations with ABO blood groups and rhesus blood group status in hemodialysis patients. In a cross-sectional study, serum samples of 151 hemodialysis patients were tested for anti-Helicobacter pylori IgG antibody. Anti-Cag A antibody [IgG antibody] was tested in Helicobacter pylori-positive patients. ABO blood groups typing and rhesus status were tested by hemagglutination test. Prevalence of anti-Helicobacter pylori and anti-Cag A antibodies in Helicobacter pylori-positive patients were 65.6% [99 of 151] and 25.3% [25 of 99], respectively. Prevalence of anti-Helicobacter pylori and anti-Cag A antibodies were 69.1% and 36.8% in patients with blood group A, 42.3% and 9.1% in blood group B, 75.0% and zero in blood group AB, 69.4% and 23.3% in blood group O, 59.0% and 30.6% in rhesus-positive status and 89.7% and 11.5% in rhesus-negative status, respectively. There was a significant correlation between the presence of anti-Helicobacter pylori and anti-Cag A antibodies and rhesus status, but no significant relation between ABO blood groups and anti-Cag A antibodies were found. Rhesus status may have an impact on the presence of anti-Helicobacter pylori and anti-Cag A antibodies. More investigations to address this correlation are necessary